{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:01:41Z","timestamp":1772215301621,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec020\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 still poses a major public health challenge worldwide and vaccination remains one of the major interventions to control the disease. Different types of vaccines approved by the World Health Organization (WHO) are currently in use across the world to protect against the disease. This study assessed the prevalence and pattern of adverse events following immunization (AEFI) after receiving COVID-19 vaccine (the Oxford-AstraZeneca vaccine) among the adult population in Sokoto metropolis, North-west, Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec021\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study among 230 adults in Sokoto metropolis who received COVID-19 vaccines. Data was collected using a structured questionnaire administered via personal phone calls to respondents who were selected via a systematic sampling technique. For data analysis, IBM SPSS version 25.0 was used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec022\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of the participants [183 (79.7%)] experienced AEFI. The most common adverse events were body weakness [157 (85%)], fever [111 (60.3%)] and headache [103 (56%)]. Up to half of the respondents that experienced AEFI said it occurred within minutes and a few hours, whereas 75 (40.8%) said it was within 2-3 days. Up to 66.3% of the adverse reactions were mild and lasted between a few hours (37.5%) and one day (31.5%); however, 15.2% of the respondents had severe reactions of which 22.7% were admitted to a health facility. The development of AEFI was linked to the presence of an underlying medical condition (p\u2009=\u20090.001), a previous history of AEFI (p\u2009=\u20090.017), and a history of drug reaction (p\u2009=\u20090.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec024\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of respondents reported adverse events following vaccination with the Oxford-AstraZeneca vaccine; body weakness, fever, and headache being the most common AEFIs. History of underlying medical condition as well as a history of adverse drug reactions were predictors of the development of adverse reactions following COVID-19 vaccination. Service providers at each COVID-19 vaccination point should always take the time to explain to vaccine recipients that adverse reactions are possible; however, they should reassure them that most ARs resolve within a few hours to a few days.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0277585","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:01:51Z","timestamp":1741795311000},"page":"e0277585","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and pattern of adverse events following COVID-19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-7016","authenticated-orcid":true,"given":"Habibullah","family":"Adamu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufyanu","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishaka Alhaji","family":"Bawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akilu Muhammad","family":"Sani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adamu Ahmed","family":"Adamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"4","key":"pone.0277585.ref001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control","volume":"9","author":"YA Helmy","year":"2020","journal-title":"J Clin Med"},{"key":"pone.0277585.ref002"},{"key":"pone.0277585.ref003","doi-asserted-by":"crossref","first-page":"25151355211059791","DOI":"10.1177\/25151355211059791","article-title":"Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic","volume":"9","author":"C Yap","year":"2021","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"3","key":"pone.0277585.ref004","first-page":"221","article-title":"Efficacy and safety of COVID-19 vaccines: a systematic review","volume":"23","author":"K Xing","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"pone.0277585.ref005","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety","volume":"14","author":"MT Mascellino","year":"2021","journal-title":"Infect Drug Resist"},{"key":"pone.0277585.ref006","first-page":"738049","article-title":"Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2","volume":"8","author":"SW Lee","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"pone.0277585.ref007","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","article-title":"Safety of COVID-19 vaccines administered in the EU: Should we be concerned?","volume":"8","author":"AF Hern\u00e1ndez","year":"2021","journal-title":"Toxicol Rep"},{"key":"pone.0277585.ref008","volume-title":"Park\u2019s textbook of preventive and social medicine","author":"K Park","year":"2011"},{"key":"pone.0277585.ref009"},{"issue":"19","key":"pone.0277585.ref010","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"SJ Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0277585.ref011","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","article-title":"Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience","volume":"36","author":"SH Kim","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"4","key":"pone.0277585.ref012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/vaccines10040546","article-title":"Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa","volume":"10","author":"AA Anjorin","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"pone.0277585.ref013","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/jmv.27655","article-title":"Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India","volume":"94","author":"SP Parida","year":"2022","journal-title":"J Med Virol"},{"issue":"22","key":"pone.0277585.ref014","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/jcm10225338","article-title":"Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe","volume":"10","author":"A Dziedzic","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0277585.ref015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13690-021-00741-x","article-title":"Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021","volume":"79","author":"YR Konu","year":"2021","journal-title":"Arch Public Health"},{"issue":"2","key":"pone.0277585.ref016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/npmj.npmj_11_22","article-title":"Adverse Events Following COVID-19 Vaccination in Rivers State, Nigeria: A Cross-Sectional Study","volume":"29","author":"AM Harry","year":"2022","journal-title":"Niger Postgrad Med J"},{"key":"pone.0277585.ref017","volume-title":"\u201cCOVID-19 vaccinations: National Daily Call-in Data\u201d October 2022. Department of Planning Research and Statistics (Offline Database)","author":"National Primary Health Care Development Agency (NPHCDA)"},{"issue":"37","key":"pone.0277585.ref018","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1016\/j.vaccine.2017.07.061","article-title":"The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations","volume":"35","author":"ADVANCE consortium","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"pone.0277585.ref019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.24874\/PES03.01.003","article-title":"Determination of sample size and sampling methods in applied research","volume":"3","author":"TS Nanjundeswaraswamy","year":"2021","journal-title":"PES"},{"issue":"2","key":"pone.0277585.ref020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21315\/mjms2021.28.2.2","article-title":"A Step-by-Step Process on Sample Size Determination for Medical Research","volume":"28","author":"MA Bujang","year":"2021","journal-title":"Malays J Med Sci"},{"key":"pone.0277585.ref021"},{"key":"pone.0277585.ref022"},{"issue":"7","key":"pone.0277585.ref023","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic","volume":"10","author":"A Riad","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"pone.0277585.ref024","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3390\/vaccines10122012","article-title":"Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study","volume":"10","author":"JM Granados Villalpando","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"pone.0277585.ref025"},{"issue":"Pt B","key":"pone.0277585.ref026","doi-asserted-by":"crossref","first-page":"108351","DOI":"10.1016\/j.intimp.2021.108351","article-title":"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran","volume":"101","author":"H Zare","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"pone.0277585.ref027","doi-asserted-by":"crossref","first-page":"FSO739","DOI":"10.2144\/fsoa-2021-0064","article-title":"An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2","volume":"7","author":"P Cerino","year":"2021","journal-title":"Future Sci OA"},{"issue":"17","key":"pone.0277585.ref028","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea","volume":"36","author":"S Bae","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"8","key":"pone.0277585.ref029","first-page":"752","article-title":"Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers","volume":"10","author":"M Klugar","year":"2021","journal-title":"Biology (Basel)"},{"issue":"25","key":"pone.0277585.ref030","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"pone.0277585.ref031","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0277585.ref032","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old."},{"key":"pone.0277585.ref033","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"C Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0277585.ref034","doi-asserted-by":"crossref","first-page":"e12753","DOI":"10.1016\/j.heliyon.2022.e12753","article-title":"Personalized predictions of adverse side effects of the COVID-19 vaccines","volume":"9","author":"E Jamshidi","year":"2023","journal-title":"Heliyon"},{"issue":"44","key":"pone.0277585.ref035","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1016\/j.vaccine.2021.09.060","article-title":"Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021","volume":"39","author":"VN Tran","year":"2021","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:02:05Z","timestamp":1741795325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277585"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Sessa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0277585","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.01.22281793","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}